Rahmani and colleagues [61] have demonstrated that co-exposure to the dual PI3K/mTOR inhibitor NVP-BEZ235 and the Bcl-2/Bcl-xL inhibitor ABT-737 strongly potentiated the cytotoxicity of single agents in AML. The gene discussed is MTOR; the disease is acute myeloid leukemia.